A Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Advanced/Metastatic RCC Patients

NCT01831973 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced/Metastasis Renal Cell Carcinoma

Interventions

DRUG: Lipotecan

Sponsor

Taiwan Liposome Company